Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole
Identifieur interne : 003242 ( Main/Exploration ); précédent : 003241; suivant : 003243Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole
Auteurs : Jeffrey N. Joyce [États-Unis] ; Steve Presgraves [États-Unis] ; Lynn Renish [États-Unis] ; Sabinne Borwege [États-Unis] ; Tracy Osredkar [États-Unis] ; Diane Hagner [États-Unis] ; Maria Replogle [États-Unis] ; Mateo Pazsoldan [États-Unis] ; Mark J. Millan [France]Source :
- Experimental neurology : (Print) [ 0014-4886 ] ; 2003.
Descripteurs français
- Pascal (Inist)
- Parkinson maladie, Récepteur dopaminergique D3, Récepteur dopaminergique D2, Système nerveux pathologie, Antiparkinsonien, In vitro, Etude comparative, Ropinirole, Dérivée, Animal, Primates, Modèle, Pramipexole, Mort cellulaire, Subchronique, Traitement, Souris, Tyrosine 3-monooxygenase, Locus niger, Aire tegmentaire ventrale, Dose forte.
English descriptors
- KwdEn :
- Animal, Antiparkinson agent, Cell death, Comparative study, D2 Dopamine receptor, D3 Dopamine receptor, Derivative, High dose, In vitro, Locus niger, Models, Mouse, Nervous system diseases, Parkinson disease, Pramipexole, Primates, Ropinirole, Subchronic, Treatment, Tyrosine 3-monooxygenase, Ventral tegmental area.
Abstract
The novel naphtoxazine derivative and preferential D, vs D2 receptor agonist, S32504, restores perturbed motor function in rodent and primate models of antiparkinsonian activity with a potency superior to those of two further, preferential D, receptor agonists, pramipexole and ropinirole. However, potential neuroprotective properties of S32054 have not, to date, been evaluated. Herein, employing several measures of cellular integrity, we demonstrate that S32504 robustly, concentration-dependently and completely protects terminally differentiated SH-SYSY cells against 1-methyl-4-phenylpyridinium (MPP+)-induced cell death in vitro. Further, S32504 was substantially more potent than pramipexole and ropinirole, the latter of which was neurotoxic at high concentrations. In vivo, subchronic treatment with low (0.25 mg/kg) and high (2.5 mg/kg) doses of S32504 prior to and during treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, provided complete protection against MPTP-induced tyrosine hydroxylase immunoreactive (TH-IR) neuronal death in the substantia nigra pars compacta and ventral tegmental area. A high dose of ropinirole (2.5 mg/kg) provided some protection but statistical significance was not attained, and a low dose (0.25 mg/kg) was ineffective. Neither drug afforded protection against the MPTP-induced loss of DA fibers in the striatum, as measured by TH-IR and dopamine transporter immunoreactive fiber counts. In conclusion, the novel naphotoxazine and dopaminergic agonist, S32504, robustly protects dopaminergic neurones against the neurotoxic effects of MPP+ and MPTP in in vitro and in vivo models, respectively. The underlying mechanisms and therapeutic pertinence of these actions will be of interest to further evaluate in view of its potent actions in behavioral models of antiparkinson activity.
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000E21
- to stream PascalFrancis, to step Curation: 000613
- to stream PascalFrancis, to step Checkpoint: 000D57
- to stream Main, to step Merge: 003720
- to stream Main, to step Curation: 003242
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Neuroprotective effects of the novel D<sub>3</sub>/D<sub>2</sub> receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole</title><author><name sortKey="Joyce, Jeffrey N" sort="Joyce, Jeffrey N" uniqKey="Joyce J" first="Jeffrey N." last="Joyce">Jeffrey N. Joyce</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Presgraves, Steve" sort="Presgraves, Steve" uniqKey="Presgraves S" first="Steve" last="Presgraves">Steve Presgraves</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Renish, Lynn" sort="Renish, Lynn" uniqKey="Renish L" first="Lynn" last="Renish">Lynn Renish</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Borwege, Sabinne" sort="Borwege, Sabinne" uniqKey="Borwege S" first="Sabinne" last="Borwege">Sabinne Borwege</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Osredkar, Tracy" sort="Osredkar, Tracy" uniqKey="Osredkar T" first="Tracy" last="Osredkar">Tracy Osredkar</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hagner, Diane" sort="Hagner, Diane" uniqKey="Hagner D" first="Diane" last="Hagner">Diane Hagner</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Replogle, Maria" sort="Replogle, Maria" uniqKey="Replogle M" first="Maria" last="Replogle">Maria Replogle</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Pazsoldan, Mateo" sort="Pazsoldan, Mateo" uniqKey="Pazsoldan M" first="Mateo" last="Pazsoldan">Mateo Pazsoldan</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychopharmacology, Institut de recherches de Servier, 125 chemin de ronde</s1><s2>78290 Croissy-sur-Seine (Paris)</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Croissy-sur-Seine (Paris)</settlement></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">04-0276961</idno><date when="2003">2003</date><idno type="stanalyst">PASCAL 04-0276961 INIST</idno><idno type="RBID">Pascal:04-0276961</idno><idno type="wicri:Area/PascalFrancis/Corpus">000E21</idno><idno type="wicri:Area/PascalFrancis/Curation">000613</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000D57</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000D57</idno><idno type="wicri:doubleKey">0014-4886:2003:Joyce J:neuroprotective:effects:of</idno><idno type="wicri:Area/Main/Merge">003720</idno><idno type="wicri:Area/Main/Curation">003242</idno><idno type="wicri:Area/Main/Exploration">003242</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Neuroprotective effects of the novel D<sub>3</sub>/D<sub>2</sub> receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole</title><author><name sortKey="Joyce, Jeffrey N" sort="Joyce, Jeffrey N" uniqKey="Joyce J" first="Jeffrey N." last="Joyce">Jeffrey N. Joyce</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Presgraves, Steve" sort="Presgraves, Steve" uniqKey="Presgraves S" first="Steve" last="Presgraves">Steve Presgraves</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Renish, Lynn" sort="Renish, Lynn" uniqKey="Renish L" first="Lynn" last="Renish">Lynn Renish</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Borwege, Sabinne" sort="Borwege, Sabinne" uniqKey="Borwege S" first="Sabinne" last="Borwege">Sabinne Borwege</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Osredkar, Tracy" sort="Osredkar, Tracy" uniqKey="Osredkar T" first="Tracy" last="Osredkar">Tracy Osredkar</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Hagner, Diane" sort="Hagner, Diane" uniqKey="Hagner D" first="Diane" last="Hagner">Diane Hagner</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Replogle, Maria" sort="Replogle, Maria" uniqKey="Replogle M" first="Maria" last="Replogle">Maria Replogle</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Pazsoldan, Mateo" sort="Pazsoldan, Mateo" uniqKey="Pazsoldan M" first="Mateo" last="Pazsoldan">Mateo Pazsoldan</name><affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Thomas H. Christopher Center for Parkinson's Diseuse Research, Sun Health Research Institute</s1><s2>Sun City, AZ 852622</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>4 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Arizona</region></placeName></affiliation></author><author><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name><affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Department of Psychopharmacology, Institut de recherches de Servier, 125 chemin de ronde</s1><s2>78290 Croissy-sur-Seine (Paris)</s2><s3>FRA</s3><sZ>9 aut.</sZ></inist:fA14><country>France</country><placeName><region type="region" nuts="2">Île-de-France</region><settlement type="city">Croissy-sur-Seine (Paris)</settlement></placeName></affiliation></author></analytic><series><title level="j" type="main">Experimental neurology : (Print)</title><title level="j" type="abbreviated">Exp. neurol. : (Print)</title><idno type="ISSN">0014-4886</idno><imprint><date when="2003">2003</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Experimental neurology : (Print)</title><title level="j" type="abbreviated">Exp. neurol. : (Print)</title><idno type="ISSN">0014-4886</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animal</term><term>Antiparkinson agent</term><term>Cell death</term><term>Comparative study</term><term>D2 Dopamine receptor</term><term>D3 Dopamine receptor</term><term>Derivative</term><term>High dose</term><term>In vitro</term><term>Locus niger</term><term>Models</term><term>Mouse</term><term>Nervous system diseases</term><term>Parkinson disease</term><term>Pramipexole</term><term>Primates</term><term>Ropinirole</term><term>Subchronic</term><term>Treatment</term><term>Tyrosine 3-monooxygenase</term><term>Ventral tegmental area</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Parkinson maladie</term><term>Récepteur dopaminergique D3</term><term>Récepteur dopaminergique D2</term><term>Système nerveux pathologie</term><term>Antiparkinsonien</term><term>In vitro</term><term>Etude comparative</term><term>Ropinirole</term><term>Dérivée</term><term>Animal</term><term>Primates</term><term>Modèle</term><term>Pramipexole</term><term>Mort cellulaire</term><term>Subchronique</term><term>Traitement</term><term>Souris</term><term>Tyrosine 3-monooxygenase</term><term>Locus niger</term><term>Aire tegmentaire ventrale</term><term>Dose forte</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The novel naphtoxazine derivative and preferential D, vs D<sub>2</sub> receptor agonist, S32504, restores perturbed motor function in rodent and primate models of antiparkinsonian activity with a potency superior to those of two further, preferential D, receptor agonists, pramipexole and ropinirole. However, potential neuroprotective properties of S32054 have not, to date, been evaluated. Herein, employing several measures of cellular integrity, we demonstrate that S32504 robustly, concentration-dependently and completely protects terminally differentiated SH-SYSY cells against 1-methyl-4-phenylpyridinium (MPP+)-induced cell death in vitro. Further, S32504 was substantially more potent than pramipexole and ropinirole, the latter of which was neurotoxic at high concentrations. In vivo, subchronic treatment with low (0.25 mg/kg) and high (2.5 mg/kg) doses of S32504 prior to and during treatment of mice with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, MPTP, provided complete protection against MPTP-induced tyrosine hydroxylase immunoreactive (TH-IR) neuronal death in the substantia nigra pars compacta and ventral tegmental area. A high dose of ropinirole (2.5 mg/kg) provided some protection but statistical significance was not attained, and a low dose (0.25 mg/kg) was ineffective. Neither drug afforded protection against the MPTP-induced loss of DA fibers in the striatum, as measured by TH-IR and dopamine transporter immunoreactive fiber counts. In conclusion, the novel naphotoxazine and dopaminergic agonist, S32504, robustly protects dopaminergic neurones against the neurotoxic effects of MPP<sup>+</sup> and MPTP in in vitro and in vivo models, respectively. The underlying mechanisms and therapeutic pertinence of these actions will be of interest to further evaluate in view of its potent actions in behavioral models of antiparkinson activity.</div></front></TEI><affiliations><list><country><li>France</li><li>États-Unis</li></country><region><li>Arizona</li><li>Île-de-France</li></region><settlement><li>Croissy-sur-Seine (Paris)</li></settlement></list><tree><country name="États-Unis"><region name="Arizona"><name sortKey="Joyce, Jeffrey N" sort="Joyce, Jeffrey N" uniqKey="Joyce J" first="Jeffrey N." last="Joyce">Jeffrey N. Joyce</name></region><name sortKey="Borwege, Sabinne" sort="Borwege, Sabinne" uniqKey="Borwege S" first="Sabinne" last="Borwege">Sabinne Borwege</name><name sortKey="Hagner, Diane" sort="Hagner, Diane" uniqKey="Hagner D" first="Diane" last="Hagner">Diane Hagner</name><name sortKey="Osredkar, Tracy" sort="Osredkar, Tracy" uniqKey="Osredkar T" first="Tracy" last="Osredkar">Tracy Osredkar</name><name sortKey="Pazsoldan, Mateo" sort="Pazsoldan, Mateo" uniqKey="Pazsoldan M" first="Mateo" last="Pazsoldan">Mateo Pazsoldan</name><name sortKey="Presgraves, Steve" sort="Presgraves, Steve" uniqKey="Presgraves S" first="Steve" last="Presgraves">Steve Presgraves</name><name sortKey="Renish, Lynn" sort="Renish, Lynn" uniqKey="Renish L" first="Lynn" last="Renish">Lynn Renish</name><name sortKey="Replogle, Maria" sort="Replogle, Maria" uniqKey="Replogle M" first="Maria" last="Replogle">Maria Replogle</name></country><country name="France"><region name="Île-de-France"><name sortKey="Millan, Mark J" sort="Millan, Mark J" uniqKey="Millan M" first="Mark J." last="Millan">Mark J. Millan</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonFranceV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003242 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 003242 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonFranceV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= Pascal:04-0276961
|texte= Neuroprotective effects of the novel D3/D2 receptor agonist and antiparkinson agent, S32504, in vitro against 1-methyl-4-phenylpyridinium (MPP+) and in vivo against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): a comparison to ropinirole
}}
| This area was generated with Dilib version V0.6.29. |  |